Inoculation: Nigeria turns to Johnson & Johnson COVID-19 Vaccine, to receive 29.8m doses

*The Federal Government discloses the aim of the new arrangement is to mitigate the negative concerns about the delayed deliveries of doses of AstraZeneca COVID-19 Vaccines, and ensure the sustained supply of vaccines for continued vaccinations in the country

Alexander Davis | ConsumerConnect

In a strategic move to alleviate the negative concerns about the delayed deliveries of doses of the AstraZeneca COVID-19 Vaccine, and ensure the sustained supply of vaccines for vaccinating millions of Nigerians, the Nigerian Government has disclosed it is expecting about 29.8 million doses of the Johnson & Johnson (J&J) COVID-19 vaccine.

Dr. Faisal Shuaib, Executive Director/ Chief Executive Officer (CEO) of the National Primary Health Care Development Agency (NPHCDA), revealed this at the weekly media briefing of the Presidential Steering Committee (PSC) on COVID-19 Monday, in Abuja, FCT.

COVID-19 vaccination

ConsumerConnect reports the J&J Janssen COVID-19 Vaccine is a single-dose virus vaccine for inoculation against the disruptive disease.

Dr. Shuaibu stated that the government signed off to receive the vaccines through the African Union (AU), while vaccine deliveries through the COVAX facility are being expected by the end of May or early June.

According to the NPHCDA Chief, by this timeline, the country will have completed the process of administering the second dose of the AstraZeneca Vaccine to those who got the first dose.

He also noted that the National Agency for Food and Drug Administration and Control (NAFDAC) has continued discussions with manufacturers to examine their vaccines, in anticipation of emergency use listing from the World Health Organisation (WHO).

He said the aim of the arrangement is to mitigate the negative concerns about the delayed deliveries of doses of AstraZeneca Vaccines, thereby ensuring the sustained supply of vaccines for the smooth continuation of the exercise in Nigeria.

As of April 26, Shuaibu said a total of 1,173, 869 Nigerians, representing 58.3 percent of the eligible persons targeted in the first phase, have received their first dose of the AstraZeneca COVID-19 Vaccine.

He, however, lamented the global scarcity of COVID-19 vaccines due to high demand, especially in countries where the vaccines were being produced.

The government anticipates a delay in vaccine supply to the country, which may also affect and impact the remaining phases of the vaccination exercise negatively.

Kindly Share This Story